Dossier assessment
Risankizumab (Crohn’s disease) - Benefit assessment according to § 35a SGB V
Report documents
-
Extract of dossier assessment
Risankizumab (Crohn’s disease) - Benefit assessment according to § 35a SGB V
-
Dossier assessment
Risankizumab (Crohn’s disease) - Benefit assessment according to § 35a SGB V
Dossier assessment
Indication:
Adults with moderately to severely active Crohn’s disease
Result of dossier assessment:
- who have had an inadequate response to, lost response to, or were intolerant to conventional therapy: added benefit not proven
- who have had an inadequate response to, lost response to, or were intolerant to a biologic therapy (TNF-alpha antagonist or integrin inhibitor or interleukin inhibitor): added benefit not proven
Additional information
Federal Joint Committee (G-BA)
2023-06-15 A G-BA decision was published.
Project details
- Project no.
- A22-133
- Commission
- Commission awarded on 21.12.2022 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Digestion, metabolism and hormones
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
Connected Projects
-
Dossier assessment
Risankizumab (psoriatic arthritis) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Risankizumab (plaque psoriasis) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Risankizumab (ulcerative colitis) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed